# Behçet Disease

Behçet disease requires phenotype-directed care: recognize clinical diagnostic patterns, urgently identify ocular, neurologic, vascular, and gastrointestinal involvement, and match immunomodulatory treatment to threatened organs rather than mucocutaneous activity alone.

**Clinical question:** How should physicians diagnose Behçet disease, identify organ-threatening involvement, and select manifestation-specific treatment?

Updated: 2026-08-24T18:22:46.917630+00:00

## What matters in practice
- Behçet disease is a clinical diagnosis; no single diagnostic test exists, so recurrent mucocutaneous disease must be assessed alongside ocular, vascular, neurologic, gastrointestinal, and articular manifestations. [14][3]
- Treat abrupt visual symptoms, retinal vasculitis, pulmonary arterial disease, cerebral venous thrombosis, focal neurologic deficits, and significant gastrointestinal bleeding or perforation as organ-threatening disease requiring urgent phenotype-specific assessment. [1][3][14][15][24]
- For recurrent mucocutaneous lesions, use topical corticosteroids for ulcers and consider colchicine first, particularly when genital ulcers or erythema nodosum predominate. [1][24]
- Endoscopy and/or imaging should confirm suspected intestinal involvement; exclude NSAID-induced and infectious ulceration before attributing lesions to Behçet disease. [24]
- Young men and patients with links to endemic regions have greater risk of severe manifestations and mortality, supporting a lower threshold to evaluate vascular, ocular, and neurologic disease. [14]

## Identify manifestations that require urgent escalation

Separate mucocutaneous flares from disease that can rapidly threaten vision, neurologic function, or life.

Arrange urgent ophthalmologic examination for red eye, new floaters, blurred vision, reduced acuity, or photophobia in a patient with suspected or established Behçet disease. Eye involvement includes anterior or posterior uveitis, vitreous inflammatory cells on slit-lamp examination, and retinal vasculitis; ocular disease is a poor-prognosis phenotype and may occur in approximately 50% of patients. [3][1][10]

Escalate immediately for focal neurologic deficits, altered cognition, severe persistent headache, or symptoms suggesting cerebral venous thrombosis. Neurologic Behçet disease requires a diagnostic evaluation that distinguishes inflammatory parenchymal disease from vascular cerebral venous disease because both alter acute management and prognosis. [3][1]

Evaluate hemoptysis, pleuritic chest symptoms, unexplained venous thrombosis, limb ischemia, or pulsatile masses as possible vascular Behçet disease. The vasculitic process can involve arteries or veins of any size, including pulmonary arteries, and pulmonary arterial aneurysm rupture is a recognized catastrophic complication. [15][14]

Assess overt gastrointestinal bleeding, acute abdominal pain, obstruction, or suspected perforation urgently. Gastrointestinal Behçet disease can produce ulceration, bleeding, and perforation; confirm inflammatory digestive involvement with endoscopy and/or imaging while excluding infectious and NSAID-related ulceration. [15][24]
- Urgent same-day ophthalmology: suspected posterior uveitis, retinal vasculitis, or any acute visual decline. [3][1]
- Urgent neurologic and vascular assessment: focal deficits, cerebral venous thrombosis syndrome, hemoptysis, or suspected pulmonary arterial involvement. [3][15]
- Urgent gastrointestinal assessment: bleeding, severe abdominal pain, or concern for perforation. [15][24]

*Organ-threatening Behçet phenotypes and immediate diagnostic direction. [1][3][15][24]*

| Clinical branch | High-risk findings | Immediate next step |
| --- | --- | --- |
| Ocular | Posterior uveitis, vitreous cells, retinal vasculitis, or visual decline [3] | Urgent ophthalmologic slit-lamp and retinal assessment; initiate organ-directed immunosuppressive planning with ophthalmology and rheumatology. [1][3] |
| Neurologic | Focal deficits, encephalopathic features, severe persistent headache, or cerebral venous thrombosis syndrome [3] | Urgent neurologic assessment to distinguish parenchymal inflammatory disease from cerebral venous disease. [3] |
| Vascular | Venous thrombosis, hemoptysis, arterial ischemia, or suspected aneurysm [15] | Urgently image the symptomatic vascular territory and assess for pulmonary arterial involvement when clinically suspected. [15][14] |
| Gastrointestinal | Bleeding, severe abdominal pain, obstruction, or perforation concern [15][24] | Perform endoscopy and/or imaging; exclude infectious and NSAID-related ulceration before assigning intestinal Behçet involvement. [24] |

## Make a clinical diagnosis and document the disease phenotype

Classification criteria can support recognition but do not replace exclusion of mimics or organ-specific evaluation.

Establish the diagnosis from the longitudinal pattern of recurrent oral and genital aphthosis, skin lesions, ocular inflammation, and compatible vascular, neurologic, gastrointestinal, or articular disease. There is no diagnostic test for Behçet disease; manifestations may occur in different combinations and may emerge sequentially over time. [14][6]

Use the 2014 International Criteria for Behçet's Disease as a structured adjunct: oral aphthosis, genital aphthosis, and ocular lesions each contribute 2 points; skin lesions contribute 1 point. Neurologic and vascular manifestations are also included in the criteria, and a pathergy test can add diagnostic support. [3]

If performing pathergy testing, have the reaction read by a clinician 24 to 48 hours after testing. A positive result supports but does not independently establish the diagnosis; its diagnostic performance varies across populations. [3][20]

Document the phenotype at every baseline assessment: mucocutaneous activity, eye disease, arthritis, vascular events, neurologic involvement, and gastrointestinal symptoms. This is essential because management is individualized according to the organ involved and its severity, and ocular, vascular, neurologic, and gastrointestinal involvement carry a poorer prognosis than isolated mucocutaneous disease. [1]
- Record recurrent oral and genital ulcer history, including prior genital scarring, because recurrent genital ulceration or scarring is a recognized diagnostic feature. [3]
- Obtain an ophthalmologic examination when ocular disease is suspected; retinal vasculitis requires ophthalmologist assessment. [3]
- Interpret HLA-B51 as an associated marker rather than a stand-alone diagnostic test. [15][19]

### Diagnostic alternatives that require active exclusion

In a patient with orogenital ulceration, do not attribute gastrointestinal ulceration to Behçet disease without excluding NSAID injury and infection. This distinction is particularly important before systemic immunosuppression because infectious ulceration requires a different treatment path. [24]

When neurologic symptoms occur, do not assume inflammatory neuro-Behçet disease without evaluating for cerebral venous thrombosis; neurologic involvement encompasses distinct parenchymal and vascular syndromes. [3]

*Clinical features that increase diagnostic confidence and direct phenotype assessment. [3][14][15]*

| Feature | Interpretation | Action |
| --- | --- | --- |
| Recurrent oral aphthosis | Core mucocutaneous feature; contributes 2 ICBD points. [3] | Elicit recurrence pattern and assess for associated genital, skin, ocular, and systemic disease. [3][14] |
| Genital aphthosis or scarring | Contributes 2 ICBD points; recurrent ulceration or scarring is a recognized diagnostic feature. [3] | Examine when active and document scars when present. [3] |
| Uveitis or retinal vasculitis | Contributes 2 ICBD points and indicates a poor-prognosis phenotype. [3][1] | Obtain urgent ophthalmology assessment and prioritize vision-preserving treatment. [1][3] |
| Skin lesions | Erythema nodosum, pseudofolliculitis, papulopustular lesions, or acneiform nodules contribute 1 ICBD point. [3] | Differentiate from acne vulgaris and use lesion phenotype to guide mucocutaneous therapy. [1][3] |
| Vascular or neurologic involvement | Supports ICBD classification and identifies potentially severe disease. [3][1] | Assess urgently for vascular anatomy and neurologic subtype. [3][15] |

## Treat recurrent mucocutaneous and articular disease stepwise

Target symptom control while repeatedly screening for a transition to ocular, neurologic, vascular, or gastrointestinal disease.

For oral and genital ulcers, use topical corticosteroids for active lesions. For prevention of recurrent mucocutaneous disease, try colchicine first, particularly when genital ulcers or erythema nodosum-like lesions are the dominant manifestations. [1]

French recommendations list colchicine 1 to 2 mg/day for mucocutaneous disease and refractory oral ulcers can be treated with apremilast 30 mg twice daily. In a phase 2 trial, apremilast reduced oral-ulcer incidence and severity; use it for oral-ulcer-predominant disease after weighing the absence of demonstrated benefit for organ-threatening disease in that trial population. [24][9]

For mucocutaneous disease not controlled with colchicine or apremilast, phenotype-directed alternatives include azathioprine 2 mg/kg/day, anti-TNF therapy, thalidomide 50 to 100 mg/day, or ustekinumab in the French recommendations. Select escalation with rheumatology input and avoid treating oral ulcers alone as a proxy for control of ocular, vascular, neurologic, or gastrointestinal disease. [24][1]

For acute arthritis, consider intra-articular corticosteroid injection, NSAIDs, or short-term oral corticosteroids. Colchicine at 1 to 2 mg/day is a listed option for articular disease; recurrent or refractory arthritis may prompt azathioprine 2 mg/kg/day, methotrexate 0.3 mg/kg/week, or anti-TNF therapy. [24]
- Papulopustular or acneiform lesions: use topical or systemic measures used for acne vulgaris. [1]
- Reassess apparent refractory mucocutaneous disease for unrecognized ocular, vascular, neurologic, or gastrointestinal activity before serially adding agents. [1]
- Avoid prolonged systemic corticosteroid dependence for isolated recurrent ulcers when steroid-sparing options are appropriate. [1][24]

*Phenotype-directed treatment options for mucocutaneous and articular Behçet disease. [1][24][9]*

| Manifestation | Initial treatment | Escalation or refractory disease |
| --- | --- | --- |
| Oral or genital ulcers | Topical corticosteroids for active ulcers; colchicine for recurrence prevention. [1] | Apremilast 30 mg twice daily for refractory mucocutaneous disease; alternatives include azathioprine 2 mg/kg/day, anti-TNF therapy, thalidomide 50-100 mg/day, or ustekinumab. [24] |
| Erythema nodosum-predominant disease | Colchicine is particularly favored as first preventive therapy. [1] | Consider systemic steroid-sparing therapy for refractory disease. [24] |
| Papulopustular or acneiform lesions | Topical or systemic acne-directed measures. [1] | Reassess for concurrent systemic Behçet activity rather than escalating acne therapy alone. [1] |
| Acute arthritis | Intra-articular corticosteroid injection, NSAIDs, short-term oral corticosteroids, or colchicine 1-2 mg/day. [24] | Azathioprine 2 mg/kg/day, methotrexate 0.3 mg/kg/week, or anti-TNF therapy for recurrent or refractory disease. [24] |

## Confirm major-organ involvement before escalating immunosuppression

The therapeutic target is control of the inflamed organ, not simply suppression of ulcers or arthralgia.

For ocular, vascular, neurologic, or gastrointestinal disease, use coordinated multidisciplinary care because treatment intensity must reflect the affected organ and severity. EULAR emphasizes individualized treatment according to age, sex, organ involvement, disease severity, and patient preferences. [1]

For confirmed digestive involvement, French recommendations use systemic corticosteroids at 0.5 mg/kg/day with azathioprine 2 mg/kg/day or 5-aminosalicylic acid. In severe disease, anti-TNF-alpha therapy is indicated; confirm disease by endoscopy and/or imaging and exclude infectious or NSAID-induced ulceration before initiating this pathway. [24]

Ocular disease merits early ophthalmology-rheumatology co-management because retinal vasculitis and posterior uveitis are vision-threatening. Evidence-based management recommendations identify immunosuppressive treatment and biologic therapy, including anti-TNF approaches, as central options for severe or refractory Behçet uveitis, while treatment selection depends on the ocular phenotype and prior response. [1][3]

Vascular disease should prompt imaging of the symptomatic territory and assessment for arterial aneurysm, particularly with thoracic symptoms or hemoptysis. Behçet disease uniquely can involve both arterial and venous beds; vascular treatment is manifestation-specific and systemic corticosteroids are described as typical therapy for vascular involvement. [15]

For neurologic Behçet disease, involve neurology and rheumatology early. Controlled treatment trials for neurologic complications remain lacking, so treatment decisions depend on whether presentation is parenchymal inflammatory disease or cerebral venous thrombosis and on clinical severity. [3]
- Do not delay ophthalmologic assessment while awaiting systemic treatment decisions in suspected retinal vasculitis or posterior uveitis. [3][1]
- Before labeling bowel lesions as intestinal Behçet disease, obtain endoscopy and/or imaging and exclude infection and NSAID injury. [24]
- In suspected vascular disease, image before invasive intervention whenever feasible because aneurysmal disease may coexist with thrombosis. [15][14]

### Pregnancy and lactation

For patients with stable disease planning pregnancy, serious vascular or neurologic disease is not considered a contraindication when remission has been maintained for at least 12 months in the French recommendations. Colchicine may be continued at the same dose during pregnancy and lactation; azathioprine, cyclosporine, and anti-TNF-alpha agents may be continued when justified by Behçet disease activity. [24]

*Major-organ Behçet disease: confirmation and treatment direction. [1][3][15][24]*

| Phenotype | Confirmatory direction | Treatment direction |
| --- | --- | --- |
| Ocular | Ophthalmologic slit-lamp evaluation and retinal assessment for uveitis, vitreous cells, or retinal vasculitis. [3] | Urgent immunosuppressive treatment planning; anti-TNF therapy is an option in severe or refractory uveitis. [1][3] |
| Gastrointestinal | Endoscopy and/or imaging; exclude NSAID-related and infectious ulcers. [24] | Systemic corticosteroids 0.5 mg/kg/day with azathioprine 2 mg/kg/day or 5-ASA; anti-TNF-alpha therapy for severe disease. [24] |
| Vascular | Image symptomatic arterial or venous territory; evaluate thoracic symptoms or hemoptysis for pulmonary arterial disease. [15][14] | Use phenotype-specific immunosuppressive management; systemic corticosteroids are typical therapy for vascular involvement. [15] |
| Neurologic | Determine whether presentation is parenchymal inflammatory disease or cerebral venous thrombosis. [3] | Early neurology-rheumatology management; treatment evidence lacks controlled trials for neurologic complications. [3] |

## Monitor by organ risk, not ulcer frequency alone

Disease manifestations may ameliorate over time, but new major-organ involvement can occur after initially limited disease.

At follow-up, ask specifically about visual change, neurologic symptoms, thrombosis symptoms, hemoptysis, gastrointestinal bleeding, abdominal pain, and new genital ulcers or skin lesions. Clinical manifestations can arise in different combinations and sequences, so isolated mucocutaneous disease does not exclude subsequent systemic involvement. [6][18]

Use a lower threshold for structured surveillance and rapid reassessment in men, younger patients, and those with genetic links to endemic regions because severe manifestations and mortality are generally greatest in men, patients younger than 35 years, and those with links to endemic areas. [14]

Base treatment de-escalation on sustained control of the highest-risk organ manifestation rather than improvement in oral ulcers alone. EULAR notes that manifestations may ameliorate over time, but ocular, vascular, neurologic, and gastrointestinal involvement remain poor-prognosis features requiring individualized management. [1]
- Document visual symptoms at every visit in patients with prior uveitis or retinal vasculitis and arrange prompt ophthalmology reassessment for recurrence. [3][1]
- Reevaluate abdominal symptoms with endoscopy and/or imaging when intestinal disease is suspected or recurs; reassess infection and NSAID exposure before intensifying immunosuppression. [24]
- Continue multidisciplinary follow-up for major-organ disease because management depends on organ involvement, severity, and treatment response. [1][24]

*Follow-up questions that identify a change in Behçet disease phenotype. [1][3][6][24]*

| New symptom or event | Concern | Next action |
| --- | --- | --- |
| Visual decline, floaters, photophobia, or red eye | Recurrent uveitis or retinal vasculitis [3] | Urgent ophthalmologic assessment. [3][1] |
| Focal neurologic symptoms or severe persistent headache | Parenchymal neurologic disease or cerebral venous thrombosis [3] | Urgent neurologic evaluation. [3] |
| Hemoptysis, venous thrombosis symptoms, or limb ischemia | Pulmonary arterial, venous, or arterial vascular involvement [15] | Urgent vascular imaging tailored to symptoms. [15] |
| Bleeding, severe abdominal pain, or obstructive symptoms | Intestinal Behçet disease or alternative ulcerative pathology [15][24] | Endoscopy and/or imaging; exclude infection and NSAID injury. [24] |

## References
1. 2018 update of the EULAR recommendations for the management ... — ard.bmj.com — https://ard.bmj.com/content/annrheumdis/early/2018/04/06/annrheumdis-2018-213225.full.pdf
2. AB0059 THE EFFECT OF GENDER ON CLINICAL ... — ard.bmj.com — https://ard.bmj.com/content/83/Suppl_1/1257.2
3. Neurological involvement by Behçet’s syndrome: clinical features, diagnosis, treatment and outcome | Practical Neurology — pn.bmj.com — https://pn.bmj.com/content/23/5/386
4. Development and preliminary validation of the Behçet's ... — rmdopen.bmj.com — https://rmdopen.bmj.com/content/rmdopen/6/2/e001192.full.pdf
5. POS1357 THE 10-YEAR OUTCOME OF PATIENTS WITH ... — ard.bmj.com — https://ard.bmj.com/content/81/Suppl_1/1017.2
6. Behcet syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/376
7. FRI0252 Behcet's Disease and Pregnancy — ard.bmj.com — https://ard.bmj.com/content/74/Suppl_2/516.1
8. Infliximab versus Cyclophosphamide for Severe Behçet's ... — evidence.nejm.org — https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300354
9. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1816594
10. Behçet's Syndrome — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMra2305712
11. Behçet's Disease Epidemiology and Clinical Management — www.nature.com — https://www.nature.com/nature-index/topics/l4/behcet-s-disease-epidemiology-and-clinical-management
12. Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-025-68100-w
13. Clinical characteristics and quality of life of patients with ... — www.nature.com — https://www.nature.com/articles/s41598-024-82102-6
14. Differential diagnosis and management of Behçet syndrome | Nature Reviews Rheumatology — www.nature.com — https://www.nature.com/articles/nrrheum.2012.156
15. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0b013e3181d4739e
16. Neutrophil Activation Promotes Fibrinogen Oxidation and ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.017738
17. Sex Differences in Peripheral Vascular Disease — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001310?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
18. Behçet's disease unraveled — journals.lww.com — https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202512050-00139
19. AB0801 NEW DIAGNOSTIC TOOL IN BEHCET'S DISEASE — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0003496724656888
20. HLA-B51 - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/hla-b51
21. Case Report Diagnosis of Behcet's disease in a young ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213007124000327
22. Behçet's disease in East African patients may not be ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1297319X10001624
23. Skin prick test with self saliva as a ... — applications.emro.who.int — https://applications.emro.who.int/imemrf/554/Egypt-Rheumatologist-2021-43-1-77-80-eng.pdf
24. French recommendations for the management of Behçet’s disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7903591

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.